Board of Directors
Christopher P. Lowe, Interim Chief Executive Officer (CEO)
Christopher P. Lowe was appointed as interim Chief Executive Office on February 9, 2014. Mr. Lowe has served as a Director of Hansen since September 2006. Mr. Lowe served as Chief Financial Officer of Anthera Pharmaceuticals, Inc., a drug development company, since November 2007, and has additionally served as its Chief Business Officer since January, 2011. Mr. Lowe served as Vice President, Finance and Administration of Asthmatx, Inc., a medical device company acquired by Boston Scientific, since September 2005 and as its Chief Financial Officer from January 2006 to November 2007. Mr. Lowe served with Peninsula Pharmaceuticals, Inc., a pharmaceutical company, as Corporate Controller from June 2004 to October 2004 and Chief Accounting Officer from October 2004 until its acquisition by Johnson & Johnson in June 2005. From January 2003 to June 2004, Mr. Lowe served as Global Divisional Controller — Trane Division with American Standard Corporation, a producer of bathroom and kitchen fixtures and fittings.. Mr. Lowe holds a B.S. from California Polytechnic State University, San Luis Obispo and an M.B.A. from Saint Mary’s University, Texas.
Michael Eagle, Chairman of the Board
Mr. Eagle joined the Hansen board in early 2012 and was named Chair of the board in Dec. 2012. He has a rich history of operational, commercial and manufacturing experience. He served as Vice President of Global Manufacturing for Eli Lilly and Company from 1994 to 2001. During his tenure, he was responsible for global production, quality, engineering, facilities, distribution, environmental conditions and safety. Mr. Eagle joined Lilly in 1983 when Lilly acquired Advanced Cardiovascular Systems where he was Sr. Vice President of Operations. Later he served as President and CEO of IVAC Corporation and Vice President of the Vascular Intervention, Medical Devices and Diagnostics Division where he oversaw the operations of four medical device subsidiaries, a technology development center and the medical device and diagnostics businesses in Japan. He served as Vice President of Pharmaceutical Manufacturing prior to his most recent position. Prior to his term at Lilly, Mr. Eagle was General Manager of Plastics Processing at IMED Corporation.
Mr. Eagle has served as a Director of a number of boards of both public and private healthcare companies including Micrus Endovascular, Inc. and Perclose, Inc. He currently serves on the board of Cadence Pharmaceuticals.
Marjorie L. Bowen, Director
Marjorie Bowen joined the Hansen Medical Board of Directors in July, 2013. Ms. Bowen is an experienced public and private company director who is a qualified financial expert and is well versed in corporate governance matters. In addition to Hansen, Ms. Bowen has served as a director for three publicly listed companies (Dune Energy, and previously, Talbots, Texas Industries, Inc.) as well as four privately held companies.
Ms. Bowen’s directorships follow a nearly 20 year career in investment banking at Houlihan Lokey, advising boards of public companies on transactional, strategic and other shareholder matters, and heading the firm’s industry leading fairness opinion practice. During her nearly two decades at Houilhan Lokey Ms. Bowen was an active deal advisor to public company boards, a product and practice leader, as well as a member of the firm’s senior management.
Ms. Bowen has amassed a broad base of experience on virtually every type of corporate finance transaction for both healthy and distressed companies. Ms. Bowen holds a BA from Colgate University and an MBA from the University of Chicago.
Kevin Hykes, Director
Kevin Hykes joined the Hansen Board of Directors in 2009. Kevin is currently the Chairman and CEO of Metavention, Inc., a Versant Ventures-backed medical device company focused on interventional therapies for type 2 diabetes and associated disorders. Prior to joining Metavention, Kevin was the President and Chief Executive Officer of Cameron Health from 2010 until its acquisition by Boston Scientific in 2012. Cameron Health was a venture-backed medical device company based in San Clemente, California which had successfully developed the world’s first and only subcutaneous implantable defibrillator.
Before joining Cameron Health, Kevin was the Chief Commercial Officer of Visiogen, Inc., a venture-backed ophthalmology company based in Irvine, California. Visiogen successfully developed and initiated European commercialization of the Synchrony Accommodating Intraocular Lens before it was acquired by Abbott Medical Optics in 2009.
Prior to joining Visiogen, Kevin spent sixteen years at Medtronic, where he held leadership positions in the Cardiac Rhythm Management, Neurological, Heart Valve, and Cardiac Surgery businesses in both the US and Europe, and served on the company’s management and operating committees. He received an MBA from the Kellogg School of Management at Northwestern University and a Bachelor’s degree from the University of Wisconsin.
Dr. Stephen Newman, Director
Dr. Newman joined the Hansen Board of Directors in January 2012. Having served in increasingly senior positions at Tenet Healthcare Corporation over the past 13 years, Dr. Newman has extensive healthcare operations experience. In his recently completed role as Vice Chairman, Dr. Newman led Tenet’s health information technology project deployment, the company’s medical staff development efforts and its quality, safety and service initiative. Prior to his appointment to Vice Chairman in January of 2012, Dr. Newman served as Corporate Chief Operating Officer, Executive Vice President, for five years, where his responsibilities included strategic and operational oversight of Tenet’s 49 hospitals and 100 ambulatory and imaging centers.
Before his tenure at Tenet, Dr. Newman served as President and Chief Executive Officer of HCA’s Louisville HealthCare Network, where he had operating responsibilities for three hospitals and 3,000 employees within a $500 million business. Dr. Newman currently serves on the Federal Reserve Bank of Atlanta’s Labor, Education and Healthcare Council and recently completed a five year term on the Board of Directors of the Federation of American Hospitals. Dr. Newman also serves on the Board of Directors of Optimer Pharmaceuticals and Cadence Pharmaceuticals.
William R. Rohn, Director
William R. Rohn, age 69, has served as a member of our Board of Directors since March 2012. Mr. Rohn served as Chief Operating Officer of Biogen Idec, the successor company to IDEC Pharmaceuticals, a biotechnology company, from 2003 until 2005. From 1998 until 2003, Mr. Rohn was President and Chief Operating Officer of IDEC Pharmaceuticals, a biotechnology company. Mr. Rohn joined IDEC in 1993 as Senior Vice President, Commercial and Corporate Development and was appointed Senior Vice President, Commercial Operations in 1996. From 1985 until 1993, Mr. Rohn was employed by Adria Laboratories, a pharmaceutical company that has since been acquired by Pfizer Inc., most recently as Senior Vice President of Sales and Marketing. Mr. Rohn is a director of Sophiris Inc. and private entities. Mr. Rohn’s knowledge of our industry and his prior and current experience as a senior officer and director of other healthcare companies contributed to our conclusion that he should serve as a director.
Jack W. Schuler, Director
Jack W. Schuler joined the Hansen Medical Board of Directors in August, 2013. Mr. Schuler is a co-founder and partner in Crabtree Partners LLC, a private investment firm in Lake Forest, IL. Mr. Schuler worked for Texas Instruments from 1964 to 1972 in France, Germany, and Japan. From 1972 to 1989, he was employed by Abbott Laboratories in various positions, the last four years as President and Chief Operating Officer. He currently serves on the board of directors for Accelerate Technologies, Quidel Corporation, and Stericycle and is a trustee of Carleton College. He received a B.S. degree in Mechanical Engineering from Tufts University and an M.B.A. degree from Stanford University Graduate School of Business Administration.
Will K. Weinstein, Director
Will K. Weinstein joined the Hansen Medical Board of Directors in July, 2013. Currently, Mr. Weinstein serves as a Financial and Investment Advisor and Money Manager to a number of individuals and corporations active in the equity markets. He is also a limited partner of Conifer Securities in San Francisco. Mr. Weinstein was a Governor of the Midwest Stock Exchange for five years, and also served for five years as a Governor of the American Stock Exchange until its merger with NASDAQ in 1998. Mr. Weinstein was Chairman and CEO of Genesis Merchant Group Securities in San Francisco from 1989 until it was sold in 1997. He then started and managed a hedge fund and two private equity partnerships. Prior to Genesis, he was the Investment and Financial Policy Advisor to the Pritzker family in Chicago. Previously, Mr. Weinstein was the Managing Partner of Montgomery Securities in San Francisco and Chairman of its Investment Policy Committee. He was also a member of the Executive Committee of Oppenheimer and Co. and its partner in charge of trading in the 1970’s.
Mr. Weinstein is a member of the board of directors of the Osher Center for Integrative Medicine in San Francisco, and he recently joined the board of the San Francisco State University Foundation, where he is a member of the endowment and athletic committees. Mr. Weinstein’s previous board affiliations include DHL Incorporated, Butterfield & Butterfield, Beverly Enterprises, Mt. Zion Hospital, the San Francisco Chapter of the Juvenile Diabetes Research Foundation, the San Francisco Performances, the Robert H. Lurie Comprehensive Cancer Center, the UCSF Department of Prostate Cancer Advocacy Core and the City College of San Francisco Foundation. He was a member of a former California Controller’s Advisory Council for Investment and served as the West Coast Chair for Bridging the Rift Foundation.
Mr. Weinstein also teaches Ethics in both the Business School and Law School at the University of Hawaii Manoa and has lectured worldwide on the subject.
Nadim Yared, Director
Nadim Yared joined the Hansen Board of Directors in 2012. Mr. Yared’s career in the medical device industry has spanned nearly 20 years. He currently serves as the President and Chief Executive Officer of CVRx, Inc., a privately-held medical device company developing the Barostim neo™ system, an active implantable device for the treatment of hypertension and heart failure. During his six years in this position, Mr. Yared has helped CVRx raise significant funding to develop the company’s next generation technology and conduct clinical trials.
Preceding his term at CVRx, Mr. Yared served as Vice President & General Manager of Medtronic Navigation for four years. During his tenure, he directed sales, marketing, business development, product/technology development and manufacturing of surgical medical imaging products. Until 2002, Mr. Yared held increasingly senior positions at GE Medical Systems over a period of nine years. Much of his focus during this time was medical device sales and marketing management. Mr. Yared also currently serves on the boards of the medical device industry trade group, AdvaMed, and Intio, a privately-held interventional oncology company.